Figure S4 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

• Combination treatment of PRMT5 and KRAS inhibitors shows effectiveness against pancreatic cancer.
• Results indicate that the treatment could be beneficial for cases with MTAP deletions.
• The study involved in vivo analyses to assess the treatment strategy's impact.
• Findings highlight the potential of using combined therapies in aggressive cancer types.